The recent wildfires in Los Angeles are just the latest in a series of natural disasters that have disrupted cancer care.

Further assessment is needed to understand if these treatment recommendations were eventually adopted and if adoption leads to better outcomes,” researchers wrote.

The FDA has authorized an expanded access program that will allow for the use of a recombinant bacillus Calmette-Guerin product.

Transdermal estradiol patches may be an alternative to LHRHas when combined with ARPIs to treat mHSPC, researchers say.

Tremtelectogene empogeditemcel (trem-cel) may make gemtuzumab ozogamicin maintenance safer for patients with high-risk acute myeloid leukemia (AML), according to results of a phase 1/2 trial presented ...

NSAID use is associated with an increased risk of death from RCC among women but not among men, researchers found.

The FDA has approved the biologics license applications for Ospomyv and Xbryk, biosimilars to Prolia and Xgeva, respectively.

Although there was a significant decline in the age-adjusted incidence-based mortality rate from 2006 to 2020, our study did not show a significant improvement in survival outcomes,” the researchers ...

(HealthDay News) — Overdiagnosis of thyroid cancer remains a persistent problem in the United States, researchers reported in The Lancet Diabetes & Endocrinology.